2Wolff AE, Jones AN, Hansen KE. Vitamin D and musculoskeletal health[J]. Nat Clin Pract Rheumatol, 2008, 4 (11): 580.
3Holick MF. High prevalence of vitamin D inad?equacy and implications for health[J]. Mayo Clin Proc, 2006, 81 (3): 353.
4Weycker D, Lamerato L, Schooley S, et al. Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoDorosis or osteopenia in clinical practice[J]. Osteoporos Int, 2013, 24 (4): 1483.
6Corrado A, Neve A, Maruotti N, et al. Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures[J]. Clin Exp Rheumatol, 2010, 28 (6): 873.
7Mori GG, Janjacomo DM, Nunes DC, et al. Effect of zoledronic acid used in the root surface treatment of late replanted teeth: a study in rats[J]. Braz Dent J, 2010, 21 (5): 452.
8Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifena results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) havestigators[J]. JAMA, 1999, 282 (7): 637.
9Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone( 1-34)on fractures and bone mineral density in postmenopausal women with os?teoporosis[J]. N Engl J Med, 2001, 344 (19): 1434.
10Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatidehuman parathyroid hormone(1-34)Jtherapy on bone density in men with osteoporosis[J]. J Bone Miner Res, 2003, 18 (1): 9.
